Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

DBV Technologies S.A. - American Depositary Shares (NQ:DBVT)

9.500 -0.088 (-0.91%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about DBV Technologies S.A. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
DBV Technologies Announces Resignation of Board Member
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
From DBV Technologies S.A.
Via GlobeNewswire
Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2025
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results
From DBV Technologies S.A.
Via GlobeNewswire
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies Announces Appointment of James Briggs as Chief Human Resources Officer
From DBV Technologies S.A.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies to Participate in Upcoming EAACI Congress 2025
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting
From DBV Technologies S.A.
Via GlobeNewswire
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of May 30, 2025
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document
From DBV Technologies S.A.
Via GlobeNewswire
PTC Therapeutics To Rally Around 61%? Here Are 10 Top Analyst Forecasts For Tuesday
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Top movers in Tuesday's session
Curious to know what's happening on the US markets one hour before the close of the markets on Tuesday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Combined General Meeting of June 11, 2025
From DBV Technologies S.A.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Why Everus Construction Group Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Information regarding the total number of voting rights and  total number of shares of the Company as of April 30, 2025
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies to Participate in the Citizens JMP Life Sciences Conference
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies Reports First Quarter 2025 Financial Results
From DBV Technologies S.A.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document
From DBV Technologies S.A.
Via GlobeNewswire
3 Biopharmaceutical Stocks Bucking the Sell-Off
Three biopharma companies may appeal to investors looking for firms that have not been rocked by tariff-inspired turbulence. 
Via MarketBeat
Topics World Trade
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Why DBV Technologies (DBVT) Stock Is Skyrocketing
DBV Technologies secured up to $306.9M to advance its Viaskin Peanut program. The funding supports FDA submission, commercialization and ongoing pediatric peanut allergy treatment research. 
Via Benzinga
Dow Tumbles Over 500 Points; Abacus Global Management Shares Spike Higher
 
Via Benzinga
Topics Stocks
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.